Optimizing Outcomes for Patients With Curable Bladder Cancer

Video
Conference|ASCO Gastrointestinal Cancer Symposium

This video highlights emerging data on genomic markers of response to neoadjuvant chemotherapy for patients with bladder cancer.

In this video, Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center in Philadelphia, discusses highlights of a session on bladder cancer from the 2017 Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.

Dr. Plimack chaired the session, which focused on optimizing outcomes in muscle-invasive bladder cancer, and gave a presentation on genomic markers of response to neoadjuvant chemotherapy. Emerging data on alterations in DNA repair genes and their association with outcomes are informing clinical trial designs with the aim of studying the feasibility of reducing treatment burden for this patient population.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content
Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Defining the Role of Immune Therapy in Multiple Myeloma

Roman Fabbricatore
August 9th 2025
Article

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as in solid tumors and beyond, includes immune therapies.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 4th 2025
Article

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 1st 2025
Article

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Russ Conroy
August 1st 2025
Article

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.